Results 41 to 50 of about 14,066,519 (402)

Overlap between adverse events (AEs) and serious adverse events (SAEs): a case study of a phase III cancer clinical trial

Trials, 2020
Background Safety data is required to be collected in all clinical trials and can be separated into two types of data, adverse events and serious adverse events.
Elizabeth C. James, David Dunn, Adrian D. Cook, Andrew R. Clamp, Matthew R. Sydes   +4 more
doaj   +1 more source

The COV-ED Survey: exploring the impact of learning and teaching from home on parent/carers’ and teachers’ mental health and wellbeing during COVID-19 lockdown

BMC Public Health, 2022
Background Following the emergence of COVID-19 in the UK, on March 18th 2020 the majority of schools in England closed and families and teachers were tasked with providing educational support for children and adolescents within the home environment ...
C Connor, N De Valliere, J Warwick, S Stewart-Brown, A Thompson   +4 more
doaj   +1 more source

Measuring and reporting quality of life outcomes in clinical trials in cystic fibrosis: a critical review [PDF]

, 2005
Good quality clinical trials are essential to inform the best cystic fibrosis (CF) management and care, by determining and comparing the effectiveness of new and existing therapies and drug delivery systems.
Abbott, Janice, Hart, Anna
core   +2 more sources

A Review of SARS-CoV-2 and the Ongoing Clinical Trials

International Journal of Molecular Sciences, 2020
The sudden outbreak of 2019 novel coronavirus (2019-nCoV, later named SARS-CoV-2) in Wuhan, China, which rapidly grew into a global pandemic, marked the third introduction of a virulent coronavirus into the human society, affecting not only the ...
Y. Tu, Chian-Shiu Chien, A. Yarmishyn, Yi-Ying Lin, Yung-Hung Luo, Yi-Tsung Lin, Wei-Yi Lai, De-Ming Yang, Shih-Jie Chou, Yi-ping Yang, Mong-Lien Wang, S. Chiou   +11 more
semanticscholar   +1 more source

A multisite study of performance drivers among institutional review boards. [PDF]

, 2017
Introduction:The time required to obtain Institutional Review Board (IRB) approval is a frequent subject of efforts to reduce unnecessary delays in initiating clinical trials. This study was conducted by and for IRB directors to better understand factors
Allen, Karen, Buscher, Nate, Caligiuri, Michael, Denney, Lisa, Firestein, Gary S, Fontanesi, John, Gates, Cynthia, Kantelo, Kip, Magit, Anthony, Sak, Rachael   +9 more
core   +1 more source

Monitoring performance of sites within multicentre randomised trials: a systematic review of performance metrics

Trials, 2018
Background Large multicentre trials are complex and expensive projects. A key factor for their successful planning and delivery is how well sites meet their targets in recruiting and retaining participants, and in collecting high-quality, complete data ...
Kate F. Walker, Julie Turzanski, Diane Whitham, Alan Montgomery, Lelia Duley   +4 more
doaj   +1 more source

Older adult participation in cancer clinical trials: A systematic review of barriers and interventions

Ca, 2020
Cancer is a disease of aging and, as the world's population ages, the number of older persons with cancer is increasing and will make up a growing share of the oncology population in virtually every country.
M. Sedrak, R. Freedman, H. Cohen, H. Muss, A. Jatoi, H. Klepin, T. Wildes, J. Le-Rademacher, G. Kimmick, W. Tew, K. George, Simran Padam, Jennifer Liu, Andrew R. Wong, A. Lynch, B. Djulbegovic, S. Mohile, W. Dale   +17 more
semanticscholar   +1 more source

Prototype of running clinical trials in an untrustworthy environment using blockchain. [PDF]

, 2019
Monitoring and ensuring the integrity of data within the clinical trial process is currently not always feasible with the current research system.
Bhattacharya, Sanchita, Butte, Atul J, Wong, Daniel R   +2 more
core   +3 more sources

Targeting PI3K in cancer: mechanisms and advances in clinical trials

Molecular Cancer, 2019
Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling is one of the most important intracellular pathways, which can be considered as a master regulator for cancer. Enormous efforts have been dedicated to the development
Jing Yang, Ji Nie, Xuelei Ma, Yuquan Wei, Yong Peng, Xiawei Wei   +5 more
semanticscholar   +1 more source

Responder Identification in Clinical Trials with Censored Data [PDF]

, 2003
We present a newly developed technique for identification of positive and negative responders to a new treatment which was compared to a classical treatment (or placebo) in a randomized clinical trial.
Kehl, V., Ulm, Kurt
core   +2 more sources